4-(1,3-Dioxolan-2-yl)cyclohexan-1-ol | 123762-03-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-(1,3-Dioxolan-2-yl)cyclohexan-1-ol
• CAS: 123762-03-8
• 化学式: C₉H₁₆O₃
• 分子量: 172.224
• InChiKey: ZKIGCBWVERTPFP-UHFFFAOYSA-N

物化性质

• 沸点：
  274.0±40.0 °C(Predicted)
• 密度：
  1.164±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  38.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-(3-cyclohexenyl)-1,3-dioxolane 生成 4-(1,3-Dioxolan-2-yl)cyclohexan-1-ol
  参考文献：
  名称：

  INOKI, SATOSHI;KATO, KOJI;TAKAI, TOSHIHIRO;ISAYAMA, SHIGERU;YAMADA, TOHRU+, CHEM. LETT.,(1989) N, C. 515-518

  摘要：

  DOI：

文献信息

• Bis(trifluoroacetylacetonato)cobalt(II) Catalyzed Oxidation-Reduction Hydration of Olefins Selective Formation of Alcohols from Olefins
  作者：Satoshi Inoki、Koji Kato、Toshihiro Takai、Shigeru Isayama、Tohru Yamada、Teruaki Mukaiyama

  DOI：10.1246/cl.1989.515

  日期：1989.3

  Various olefins are hydrated with molecular oxygen (oxidant) and a secondary alcohol (reductant) in the presence of a catalytic amount of bis(trifluoroacetylacetonato)cobalt(II) in good yields.

  在催化量的双（三氟乙酰丙酮合）钴 (II) 存在下，各种烯烃与分子氧（氧化剂）和仲醇（还原剂）以良好的产率水合。
• EGFR KINASE KNOCKDOWN VIA ELECTROPHILICALLY ENHANCED INHIBITORS
  申请人：MILLER Richard

  公开号：US20100144705A1

  公开（公告）日：2010-06-10

  Provided herein are electrophilically enhanced kinase inhibitors. Also provided herein are methods of making and utilizing the same.

  本文提供了电亲性增强激酶抑制剂。本文还提供了制备和利用这些抑制剂的方法。
• SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK AND THEIR PREPARATION AND USE IN THE TREATMENT OF CANCER, INFLAMMATION AND AUTOIMMUNE DISEASE
  申请人：BEIJING SYNERCARE PHARMA TECH CO., LTD.

  公开号：US20160237075A1

  公开（公告）日：2016-08-18

  Compounds of Formula I, as shown below and defined herein: and pharmaceutically acceptable salts, syntheses, intermediates, formulations, and methods of treating diseases including cancer, inflammation, and autoimmune disease mediated at least in part by Bruton's Tyrosine Kinase (BTK).

  化学式为I的化合物，如下所示，其定义如下：以及药学上可接受的盐，合成物，中间体，制剂和治疗疾病的方法，包括由布鲁顿酪氨酸激酶（BTK）介导的癌症，炎症和自身免疫疾病。
• Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-Like Proteins
  申请人：AC Immune SA

  公开号：US20160158242A1

  公开（公告）日：2016-06-09

  The present invention relates to novel compounds that can be employed in the treatment of a group of disorders and abnormalities associated with amyloid protein, such as Alzheimer's disease, and of diseases or conditions associated with amyloid-like proteins. The compounds of the present invention can also be used in the treatment of ocular diseases associated with pathological abnormalities/changes in the tissues of the visual system. The present invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the preparation of medicaments for treating or preventing diseases or conditions associated with amyloid and/or amyloid-like proteins. A method of treating or preventing diseases or conditions associated with amyloid and/or amyloid-like proteins is also disclosed.

  本发明涉及一种新型化合物，可用于治疗与淀粉样蛋白相关的一组疾病和异常，如阿尔茨海默病，以及与淀粉样蛋白类似蛋白相关的疾病或病况。本发明的化合物还可用于治疗与视觉系统组织病理异常/变化相关的眼部疾病。本发明还涉及包含这些化合物的药物组合物，以及使用这些化合物制备治疗或预防与淀粉样和/或淀粉样类似蛋白相关的疾病或病况的药物的用途。还公开了一种治疗或预防与淀粉样和/或淀粉样类似蛋白相关的疾病或病况的方法。
• INOKI, SATOSHI;KATO, KOJI;TAKAI, TOSHIHIRO;ISAYAMA, SHIGERU;YAMADA, TOHRU+, CHEM. LETT.,(1989) N, C. 515-518
  作者：INOKI, SATOSHI、KATO, KOJI、TAKAI, TOSHIHIRO、ISAYAMA, SHIGERU、YAMADA, TOHRU+

  DOI：——

  日期：——